Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

Hemorrhagic encephalopathy associated with COVID-19

Jonathan D. Krett⁎, Gordon A.E. Jewetta, Charissa Elton-Lacassec, Kevin Fonsecab, Christopher Hahnab, Selena Au†, Marcus W. Kochd

a Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
b Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
c Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada
d Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada

ARTICLE INFO

Keywords:
COVID-19
Encephalopathy
SARS-CoV-2
Coronavirus
Intracerebral hemorrhage

ABSTRACT

The mechanisms for neurological complications of COVID-19, the disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), are not yet well understood. We present a critically ill man with a COVID-19-associated hemorrhagic encephalopathy. SARS-CoV-2 RNA was not detected in cerebrospinal fluid (CSF) or blood. CSF analyses suggested dysregulation of pro-inflammatory cytokine pathways, particularly tumor necrosis factor-α and interleukin-6, consistent with a cytokine release syndrome. The patient gradually recovered with supportive care and neurological rehabilitation. Awareness of this clinical entity may facilitate the identification of patients with a potentially remediable cause of encephalopathy in COVID-19.

1. Introduction

COVID-19, the disease caused by infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a rapidly evolving and deadly global pandemic. Clinical presentations of COVID-19 range from mild nonspecific symptoms to critical illness from multi-organ failure. Neurological manifestations such as loss of taste or smell, seizure, and stroke have been observed and occur more frequently in more severely affected patients (Mao et al., 2020). Mechanisms for central nervous system (CNS) injury in the context of SARS-CoV-2 infection are an area of active discovery. Here we report the case of a patient with COVID-19 who presented with altered mental status progressing to severe cortical dysfunction. We describe brain magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) findings suggestive of a parainfectious hemorrhagic encephalopathy.

2. Case description

A 69 year-old man with a history of coronary artery disease, hypertension, and type 2 diabetes mellitus was admitted to hospital with acute encephalopathy and respiratory distress. Twelve days before admission he returned to Canada from a populous city in the United States, the last stop on an international journey. Four days before admission, symptoms of cough and fatigue prompted a nasopharyngeal swab for COVID-19, which tested positive for SARS-CoV-2 RNA by reverse transcriptase polymerase chain reaction (RT-PCR). The patient's neighbour called emergency services for increasing confusion over two days prior to admission.

On presentation the patient was hemodynamically stable, tachypneic, and hypoxemic requiring 3 L/min supplemental oxygen. He was alert and disoriented without lateralizing neurological deficits, but required sedation and intubation due to severe agitation. His chest radiograph was consistent with viral pneumonia from COVID-19. Initial evaluation for encephalopathy included an unremarkable computed tomography (CT) scan of the head (Fig. 1). CSF protein was elevated without pleocytosis or evidence of a culprit pathogen (Supplementary Table S1). Prerenal acute kidney injury, euglycemic diabetic ketoacidosis, E. coli urinary tract infection, and moderate hypoxemia were managed and improved. The patient required minimal vasopressor support while in intensive care.

Thirteen days into the admission, the patient progressed from inconsistently following commands to being unresponsive and diffusely paretic without sedation. Neurological examination showed limited spontaneous respirations requiring controlled ventilation. His eyes were open spontaneously, conjugate and in midline. He did not follow commands to move his eyes or extremities. Pupillary, corneal, oculo-cephalic, gag, and cough responses were present and normal. He grimaced to central pain and had absent motor responses in the
extremities to noxious stimuli. There were spontaneous, brief, flexion
and pronation movements involving the arms. His tone was flaccid in
the extremities with areflexia apart from a preserved left triceps reflex.

A gadolinium-enhanced cranial MRI (Fig. 2) showed multi-
compartmental hemorrhages with mild surrounding vasogenic edema
and no abnormal enhancement. CT/CT angiogram of the head revealed
no underlying vasculopathy (Supplementary Fig. S1). MRI of the spine
with gadolinium was unremarkable. Laboratory results showed uremia
(blood urea nitrogen 38 mmol/L, creatinine 107 μmol/dL), hypernatremia
(150 mmol/L), and ongoing hypoxemia (PaO2/FiO2 ratio 165),
but did not explain the degree of encephalopathy. Laboratory para-
parameters did not show a bleeding diathesis. The platelet count was
normal. International normalized ratio was borderline elevated at
1.1–1.3, with a normal partial thromboplastin time and no biochemical
evidence of disseminated intravascular coagulation. Although sero-
ologies for lupus anticoagulant and beta-2-glycoprotein-1 were not eval-
uated, serum studies for anticardiolipin antibodies were negative.
Electroencephalography showed generalized slowing with no focal
abnormalities or epileptiform discharges. Electromyography/nerve
conduction studies were confounded by extremity edema and could not
rule in an axonal or demyelinating neuropathy.

On day 14, CSF and blood tested negative for SARS-CoV-2 RNA by
RT-PCR (Alberta Provincial Virology Laboratory), while nasophary-
geal and endotracheal samples remained positive. We examined so-
luble cytokine receptor levels in CSF from day 1 and 14 with a multi-
plex assay (Human Soluble Cytokine 14-Plex Clinical RUO Discovery
Assay, Eve Technologies, Calgary, Canada). The samples showed high
levels of the soluble receptors for interleukin-1 (sIL-1R), interleukin-6
(sIL-6R), soluble glycoprotein-130 (sgp130), and tumor necrosis factor-
α (sTNFR) (Table 1). Based on the absence of pleocytosis and viral RNA
in the CSF, we diagnosed a parainfectious encephalopathy. Off-label
treatment with oral hydroxychloroquine was prescribed for a total of
seven days based on in vitro data suggesting it can attenuate cytokine
production in pre-treated microglia (Koch et al., 2015). A repeat MRI of
the brain with gadolinium on day 21 demonstrated expected temporal
evolution of the hemorrhagic lesions (Supplementary Fig. S2). Two
months following admission, the patient gradually recovered. He was
transferred to a neurorehabilitation unit with mild residual physical
and cognitive impairments.

3. Discussion

Early experience with COVID-19 suggests that non-specific neuro-
logic manifestations can occur in upwards of one-third of patients (Mao
et al., 2020). Here, we report encephalopathy with multifocal cerebral
hemorrhages in a COVID-19 patient with severe, otherwise unexplained
cortical dysfunction. The combined absence of pleocytosis and SARS-
CoV-2 RNA in CSF suggest against encephalitis, and no competing
etiology was identified. A CSF cytokine receptor assay used experi-
mentally showed pro-inflammatory cytokine dysregulation, particularly
of the TNF-α and IL-6 systems. These findings led us to suspect para-
infectious inflammation as a key disease mechanism. With supportive
care and rehabilitation, the patient gradually recovered.

Acute necrotizing encephalopathy (ANE) is a rare parainfectious

Fig. 1. Non-contrast CT of the head on admission to hospital (day 0).
Axial images show no acute pathology to explain the clinical presentation. Chronic microangiopathic disease can be appreciated, along with age-appropriate mild
generalized brain atrophy.
encephalopathy which presents with hemorrhagic brain lesions and mostly affects children with influenza. ANE is thought to be caused by a cytokine release syndrome, including dysregulation of the TNF-α and IL-6 systems (Aiba et al., 2001). Recently, a case of an adult with COVID-19 who presented with imaging features of ANE was published (Poyiadji et al., 2020). Unfortunately, a traumatic lumbar puncture limited CSF analysis in that case. While our patient did have some imaging features resembling ANE, his MRI did not demonstrate the typical medial thalamic lesions or abnormal contrast enhancement (Wong et al., 2006).

Direct invasion of CNS tissue by SARS-CoV-2 has been confirmed by ultrastructural analysis of a patient autopsy (Bulfamante et al., 2020). As reported by others, patients with neurological manifestations of COVID-19 have yielded mostly negative results with respect to CSF RT-PCR for SARS-CoV-2 RNA (Helms et al., 2020; Li et al., 2020), with positive results in a single case (Moriguchi et al., 2020). Reasons for this may relate to test sensitivity, timing, and whether neurological involvement is due to direct CNS injury or an epiphenomenon of severe systemic disease. A theoretical model suggests that clinical illness from COVID-19 may occur after the peak period of SARS-CoV-2 neuroinvasion (Panciani et al., 2020); where viral RNA titres within CSF fall below assay detection limits despite evolving CNS injury. SARS-CoV-2 RNA was not detected in the CSF of our patient during his established encephalopathy, yet pro-inflammatory cytokine dysregulation was apparent. Therefore, parainfectious inflammation may be a contributor. We cannot exclude direct viral neuroinvasion as a factor which triggers or sustains the illness.

A macrovascular explanation for our patient’s intracranial hemorrhages was not found; however microvascular inflammation may play a role. SARS-CoV-2 infiltration and subsequent inflammation of vascular endothelial cells has been observed pathologically in multiple extracerebral tissues (Varga et al., 2020). Furthermore, reports of acute cerebrovascular events in otherwise healthy COVID-19 patients suggest vascular endothelial dysfunction as a potential disease mechanism (Saiegh et al., 2020; Oxley et al., 2020). This raises the possibility that our patient’s concomitant CSF cytokine dysregulation and intracranial hemorrhages may relate to unique aspects of SARS-CoV-2 pathophysiology. As for hemorrhage precipitants, we did not find laboratory evidence of a coagulopathy in our patient. Combined pro-thrombotic and pro-hemorrhagic states have been reported in the context of an antiphospholipid antibody syndrome in COVID-19 patients (Zhang et al., 2020). Unlike the cases in this report, anticardiolipin antibodies were negative in our patient. The status of the other antiphospholipid antibodies is unknown.

Severe presentations of COVID-19 are associated with elevated systemic inflammatory markers, mediating a ‘cytokine storm’ that contributes to tissue damage (Mehta et al., 2020). Several soluble cytokine receptors were elevated in our patient’s CSF, most notably the TNF-α (sTNFR1 and sTNFR2) and IL-6 (sIL-6R and sgp130) signaling systems (Table 1). Although this finding is intriguing, CSF reference ranges for the cytokine receptor assay have not been validated using data from healthy controls (see Table 1 for details). In addition, no

Fig. 2. MRI of the brain on day 13. Axial fluid-attenuated inversion recovery (FLAIR) [A-C] and susceptibility-weighted images (SWI) [D-F] demonstrate multifocal, multicompartimental hemorrhages with peri-hemorrhage vasogenic edema. Arrows show small hemorrhages in the subarachnoid space. MRI brain with gadolinium (not shown) demonstrated no abnormal contrast enhancement.
Table 1  
Cerebrospinal fluid (CSF) soluble cytokine receptor profile results from day 1 and day 14.

| Value          | Units | Day 1          | Day 14          | 95% Range* |
|----------------|-------|----------------|-----------------|-----------|
| sCD30          | pg/ml | 3.88           | 0.01            | 0–27.7    |
| sEGFR          | pg/ml | 773.16         | 8048.82         | 1852–7958 |
| sIL-1R1        | pg/ml | 6.13           | 3.36            | 0–15.2    |
| sIL-1R2        | pg/ml | Not detectable | Not detectable  | 0–364     |
| sIL-2Rα        | pg/ml | 5.35           | 12.08           | 0–240     |
| sIL-4R         | pg/ml | 0.01           | 0.01            | 0–35.2    |
| sIL-6R         | pg/ml | 1445.88        | 1627.28         | 396–1553  |
| sgp130         | pg/ml | 47.407.19      | 67.658.05       | 15.23–62,771 |
| sHAGE          | pg/ml | 1.36           | 0.27            | 0–4.1     |
| sTNFRI         | pg/ml | 1597.91        | 2402.78         | 253–1309  |
| sTNFR1         | pg/ml | 2513.66        | 3684.47         | 308–2760  |
| sVEGFR1        | pg/ml | 98.02          | 132.99          | 0–286.7   |
| sVEGFR2        | pg/ml | 2121.42        | 2700.49         | 388–2102  |
| sVEGFR3        | pg/ml | 12.96          | 7.92            | 0–65.1    |

Human Soluble Cytokine Receptor Panel (MILLIPLEX® assay, EMD MilliporeSigma). *Range depicts the 5th and 95th percentile based on the normal distribution provided by Eve Technologies, Calgary, Alberta, Canada. This distribution is derived from 124 patient CSF samples submitted to the laboratory (22 for research use, 102 for experimental clinical diagnostic use). Note that this is not a true ‘reference range’ since none of the patient samples are from healthy controls. The application of this assay is for research purposes only. Inter-assay coefficient of variation (CV) is less than 15% according to EMD MilliporeSigma.

References

Alba, H., Machizuki, M., Kimura, M., Hojo, H., 2001. Predictive value of serum interleukin-6 level in influenza virus-associated encephalopathy. Neurology 57, 295–299. https://doi.org/10.1212/wnl.57.2.295.

Bifulcante, G., Chiumento, D., Canepa, M.P., Priore, A., Mazzanti, M., Centanni, S., Felsulli, G., 2020. First ultrastructural autopsic findings of SARS-CoV-2 in olfactory pathways and brainstem. Minerva Anestesiol. https://doi.org/10.23736/S0375-9393.20.14772-2.

Cytokine dysregulation requires further investigation as a mechanism for CNS injury associated with COVID-19. The true incidence of parainfectious encephalopathy associated with COVID-19 is unknown. As the pandemic sweeps the globe, vigilance for this clinical entity is needed.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Patient consent for publication

Informed consent was obtained from the patient to publish this report.

Author contributions

JDK, GAEJ, CEL, KF, SA and MWK participated in the clinical care for this patient. JDK and GAEJ wrote the first draft of the manuscript. All authors participated in the writing and interpretation of the clinical and investigation findings, and in the writing and revision of the manuscript.

Declaration of Competing Interest

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jneuroim.2020.577326.